Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Bilibili Inc (BILI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Bilibili Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.89 (market cap $4.49B), while Bilibili Inc trades at $18.07 (market cap $7.28B). The key difference: Bilibili Inc is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Bilibili Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | BILI | |
|---|---|---|
Market Cap | $4.49B | $7.28B |
Sector | Health | Media |
52-Week High | $28.06 | $35.92 |
52-Week Low | $20.06 | $15.96 |
Enterprise Value | $3.69B | $5.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Bilibili (BILI) trades at $17.90, up 4.43% today, with a bullish technical signal despite mixed moving average indicators. The company reported Q1 2026 EPS of $0.19, beating expectations, and maintains strong analyst support with 83% buy ratings. Recent news highlights a new $300 million share repurchase program and continued user growth, though revenue expansion remains moderate.
The outlook is positive given earnings beats and shareholder-friendly buybacks, but risks include competitive pressures in China's video platform market and reliance on advertising growth. Upside potential hinges on margin expansion and successful AI integration, while macroeconomic volatility poses a headwind.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Bilibili Inc
Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.
Read more on BILI →
